Coherus Oncology, Inc.(CHRS)Earnings, Financials & Key RatiosCoherus Oncology, Inc. (CHRS) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on external capital to sustain operations, coupled with a 2026Q1 net loss of $37.9M, suggests significant ongoing liquidity risk for shareholders.
Coherus Oncology, Inc. (CHRS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Coherus Oncology, Inc. (CHRS) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.25vs $0.26+5.1% | $12Mvs $14M-13.4% |
| Q2 2026 | Mar 9, 2026 | $0.34vs $0.36+4.2% | $13Mvs $14M-8.4% |
| Q4 2025 | Nov 6, 2025 | $0.33vs $0.32-3.1% | $12Mvs $14M-17.9% |
| Q3 2025 | Aug 7, 2025 | $0.34vs $0.31-9.7% | $10Mvs $12M-14.5% |
Recent stock market news and headlines for Coherus Oncology, Inc. (CHRS)
– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor – – First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor –
Key metrics vs top competitors for Coherus Oncology, Inc. (CHRS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.44 | $176.27M | -0.99 | -84.2% | -403.8% | -279.1% | — | |
| $10.31 | $1.43B | -1.00 | -2.75% | -43.5% | -50.65% | — | |
| $16.97 | $5.41B | 77.14 | 8.05% | 4.02% | — | — | |
| $10.78 | $1.88B | 4.15 | -12.73% | 77.53% | 46.37% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — | |
| $4.62 | $293.66M | -3.92 | 0.78% | -44.79% | -147.8% | — |
Coherus Oncology, Inc. (CHRS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Coherus Oncology, Inc. (CHRS) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 11, 2026·SEC
Mar 9, 2026·SEC
Feb 17, 2026·SEC
Get notified when CHRS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Coherus Oncology, Inc. (CHRS) stock FAQ — growth, dividends, profitability & financials explained
Coherus Oncology, Inc. (CHRS) reported $46.9M in revenue for fiscal year 2025. This represents a 2369% increase from $1.9M in 2012.
Coherus Oncology, Inc. (CHRS) saw revenue decline by 84.2% over the past year.
Coherus Oncology, Inc. (CHRS) reported a net loss of $151.7M for fiscal year 2025.
Coherus Oncology, Inc. (CHRS) has a return on equity (ROE) of -279.1%. Negative ROE indicates the company is unprofitable.
Coherus Oncology, Inc. (CHRS) had negative free cash flow of $170.6M in fiscal year 2025, likely due to heavy capital investments.
